Therapeutic Areas - Biognosys
Contact us Helpdesk

Therapeutic Areas

    Biognosys’ proteomics solutions are applicable across a broad range of therapeutic areas. Our research has already made an impact in over 20 disease indications.

    By adding our cutting-edge proteomics expertise to your research, we reveal a deeper understanding of the underlying biology and provide actionable knowledge to accelerate and de-risk your research in your therapeutic areas of interest. No matter which disease indications you are working on, our next-generation proteomics applications will give you the key insights you need to advance your research.

    From basic research to early drug discovery and late-stage clinical development, Biognosys’ proteomics solutions can provide key insights into cancer disease biology and reveal the mechanism of action of novel therapeutics.

    Gaining deeper functional knowledge of how therapy or disease alters the proteome can lead to the identification of proteomic signatures that act as biomarkers to monitor or predict response to therapy and anticipate adverse events, ultimately reducing the risk of failure in drug development.

    Blood-based Biomarker Discovery

    Deep proteomics characterization of biofluids

    Biognosys’ Discovery Proteomics approach offers a highly reproducible and scalable workflow for analyzing biofluids such as blood plasma or serum, making it the ideal choice for your biomarker research needs.

    Our plasma/serum workflow enables robust and reproducible quantification of 600+ proteins in plasma or serum samples across large-scale studies. The use of our proprietary reference kit PQ500 enables the absolute quantification of up to 500 proteins in human plasma or serum.

    For deeper profiling and exploration of lower abundant proteins, we have developed a workflow that depletes samples of the most common plasma proteins to reveal the less abundant informative molecules, allowing the quantification of 1’000+ proteins.

    Browse the case studies below to see the power of our blood-based proteomics workflows to identify novel biomarkers associated with disease progression and response to therapy in lung cancer.

    Tissue Biomarker Discovery

    Global proteomic profiling of tumors to identify novel biomarkers

    Biognosys’ proteomics workflows enable the identification of dysregulated proteins in
    disease, revealing deep insights into cancer biology and new biomarkers for further
    exploration.
    Biognosys’ Discovery Proteomics approach was used to deeply characterize global tumor
    proteomes from melanoma FFPE sections to uncover proteins and pathways implicated
    in the disease, highlighting potential biomarkers associated with response after
    immunotherapy.

    Mechanism of Action

    Profiling of the proteomic response to therapy in animal models

    Proteomic profiling of tissue or tumor samples from animal models of disease reveals
    detailed information about the proteins and pathways involved in response to therapy.
    For example, Biognosys’ Discovery Proteomics was used to investigate the role of
    immune cell depletion in the response to PD-1 blockade in syngeneic mouse models.

    Phosphorylation Profiling

    Profiling of phosphorylation sites in the cancer proteome

    The discovery proteomics approach offers a scalable workflow to
    reliably and reproducibly profile thousands of samples from multiple
    time points, making it the ideal choice for clinical biomarker studies.
    In partnership with Indivumed, we have developed a high-throughput
    Discovery Proteomics workflow for the acquisition of large-scale deep
    proteomics and phospho-proteomics datasets from a longitudinal cohort
    of matching fresh-frozen tumor and adjacent healthy tissue samples
    from thousands of cancer patients. The data is being used to enrich
    Indivumed’s unique collection of biobank specimens.

    We are very excited to partner with Biognosys. Proteomics and phosphoproteomics play a crucial role in understanding cancer biology and adding Biognosys’ technology to the IndivuType multi-omics profile will enable relevant discoveries in our collaborations with pharma and biotech.

    Dr. Hartmut Juhl CEO and founder, Indivumed

    Small Molecule Target Deconvolution

    Proteome-wide characterization of the binding specificity and selectivity of small molecules

    Biognosys’ drug Target Deconvolution approach Limited Proteomics
    Mass Spectrometry (LiP-MS) can effectively identify protein drug
    targets and characterize their binding properties in complex proteomes
    without the need for compound modification or labeling.
    In this specific example, LiP-MS was used to distinguish the specificity
    and selectivity of different kinase and phosphatase inhibitors.

    The LiP technology is a very valuable tool to identify target and offtarget of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.

    Thomas Knobloch Laboratory Manager, Bayer

    The limited success of disease-modifying drugs for neurological disorders highlights the urgent need for better biomarkers and a deeper understanding of the underlying biology.

    Proteomics can provide unprecedented functional insights into the molecular basis of complex neurological disorders, bringing hidden pathways and new therapeutic targets to light.

    Biomarker Discovery in Neurodegenerative Diseases

    Global proteomic profiling of CSF to identify novel disease biomarkers

    Progress in neurodegenerative conditions such as Alzheimer’s disease has been
    hindered by a lack of knowledge about the underlying biological processes and
    relevant biomarkers. By applying Biognosys’ Discovery Proteomics workflow, we
    deeply characterized the proteome of cerebrospinal fluid samples (CSF) of
    Alzheimer’s patients to identify proteins and pathways implicated in the progression
    of the disease.

    Small Molecule Target Deconvolution

    Proteome-wide characterization of the binding specificity and selectivity of small molecules

    Biognosys’ drug Target Deconvolution approach Limited Proteomics
    Mass Spectrometry (LiP-MS) can effectively identify protein drug
    targets and characterize their binding properties in complex proteomes
    without the need for compound modification or labeling.
    In this specific example, LiP-MS was used to distinguish the specificity
    and selectivity of different kinase and phosphatase inhibitors.

    The LiP technology is a very valuable tool to identify target and offtarget of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.

    Thomas Knobloch Laboratory Manager, Bayer

    The recent success of immunotherapy has demonstrated the utility of harnessing the immune response for treating cancer and autoimmune disease. Deep quantitative proteomics offers the ability to go beyond known immunological markers and identify novel pathways and proteins that are implicated in the response to immunotherapy.

    Immune Cell Profiling

    High-dimensional proteomic characterization of immune cell phenotypes

    Immune cells are highly heterogeneous, requiring careful analysis at the level of small
    subsets or single cells. In this study, we used Biognosys’ Discovery Proteomics to
    provide a high-dimensional phenotypic characterization of sorted immune cell
    populations.

    Going far beyond the known cell surface markers used in affinity-based approaches,
    we were able to identify thousands of novel proteins and pathways that distinguish
    specific immune cell subsets. This detailed proteomic data enables an in-depth
    analysis of the processes driving immune cell activation and suppression.

    Mechanism of Action

    Profiling of the proteomic response to therapy in animal models

    Proteomic profiling of tissue or tumor samples from animal models of disease reveals
    detailed information about the proteins and pathways involved in response to therapy.

    For example, Biognosys’ Discovery Proteomics was used to investigate the role of
    immune cell depletion in the response to PD-1 blockade in syngeneic mouse models.

    Small Molecule Target Deconvolution

    Proteome-wide characterization of the binding specificity and selectivity of small molecules

    Biognosys’ drug Target Deconvolution approach Limited Proteomics
    Mass Spectrometry (LiP-MS) can effectively identify protein drug
    targets and characterize their binding properties in complex proteomes
    without the need for compound modification or labeling.

    In this specific example, LiP-MS was used to distinguish the specificity
    and selectivity of different kinase and phosphatase inhibitors.

    The LiP technology is a very valuable tool to identify target and offtarget of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.»

    Thomas Knobloch Laboratory Manager, Bayer

    The unique molecular characteristics of rare diseases pose significant challenges for drug discovery. Proteomics tools such as mass spectrometry offer a versatile, reliable platform for deep phenotyping of genetic variants and uncovering previously unknown mechanisms of disease.

    Validation of CRISPR Gene Knockouts

    Functional insights into genetically modified systems

    Gene editing tools such as CRISPR-Cas9 have revolutionized rare disease research.
    Highly targeted genetic modification allows high-throughput screening for target
    identification or validation, and rapid generation of cellular or animal models.
    Biognosys’ Discovery Proteomics profiling enables rapid and functional validation of
    targets in pre-clinical models, as well as the characterization of any secondary
    downstream consequences of gene modification.

    Small Molecule Target Deconvolution

    Proteome-wide characterization of the binding specificity and selectivity of small molecules

    Biognosys’ drug Target Deconvolution approach Limited Proteomics
    Mass Spectrometry (LiP-MS) can effectively identify protein drug
    targets and characterize their binding properties in complex proteomes
    without the need for compound modification or labeling.

    In this specific example, LiP-MS was used to distinguish the specificity
    and selectivity of different kinase and phosphatase inhibitors.

    The LiP technology is a very valuable tool to identify target and offtarget of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.»

    Thomas Knobloch Laboratory Manager, Bayer

    Chronic diseases, such as cardiovascular disease and diabetes, represent a large unmet medical need.
    Proteomics-based approaches can accelerate the discovery and development of reliable biomarkers to improve
    the diagnosis of chronic diseases and to monitor treatment response. Biognosys’ Discovery Proteomics is the
    ideal tool to guide the development of safer and targeted therapies for a wide range of chronic conditions.

    Large-scale Longitudinal Proteomics Studies in Plasma

    Deep proteomics characterization of blood-based biomarkers

    Comprehensive, high throughput profiling of the plasma proteome
    enables a holistic analysis of the health of an individual. In
    collaboration with Nestlé, Biognosys’ Discovery Proteomics was used
    in a large-scale plasma study of more than 1,500 samples collected
    over a longitudinal clinical study of weight loss. The analysis revealed
    biomarkers associated with obesity, cardiovascular and liver-associated diseases, and diabetes.